US20200139071A1 - Systems for generating nitric oxide - Google Patents
Systems for generating nitric oxide Download PDFInfo
- Publication number
- US20200139071A1 US20200139071A1 US16/444,791 US201916444791A US2020139071A1 US 20200139071 A1 US20200139071 A1 US 20200139071A1 US 201916444791 A US201916444791 A US 201916444791A US 2020139071 A1 US2020139071 A1 US 2020139071A1
- Authority
- US
- United States
- Prior art keywords
- gas
- ventilator
- nitric oxide
- nitrogen dioxide
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 143
- 239000007789 gas Substances 0.000 claims abstract description 67
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 claims abstract description 58
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims abstract description 58
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- 229960005070 ascorbic acid Drugs 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 229920005992 thermoplastic resin Polymers 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000009428 plumbing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034388 Mountain sickness acute Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 208000018315 acute mountain sickness Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0051—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B21/00—Nitrogen; Compounds thereof
- C01B21/20—Nitrogen oxides; Oxyacids of nitrogen; Salts thereof
- C01B21/24—Nitric oxide (NO)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A61M16/16—Devices to humidify the respiration air
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
- A61M2016/102—Measuring a parameter of the content of the delivered gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
Definitions
- This description relates to systems for generating nitric oxide.
- Nitric oxide also known as nitrosyl radical
- NO is a free radical that is an important signaling molecule.
- NO causes smooth muscles in blood vessels to relax, thereby resulting in vasodilation and increased blood flow through the blood vessel.
- NO gas is supplied in a bottled gaseous form diluted in nitrogen gas (N 2 ).
- N 2 nitrogen gas
- O 2 oxygen
- NO 2 nitrogen dioxide
- the part per million levels of NO 2 gas is highly toxic if inhaled and can form nitric and nitrous acid in the lungs.
- the system includes a first gas source providing nitrogen dioxide mixed in air or oxygen, and a second gas source supplying compressed air and/or compressed oxygen.
- the system also includes a ventilator coupled to the first and second gas sources, wherein the ventilator is resistant to nitrogen dioxide.
- the ventilator regulates gas flow and allows for the adjustment of nitrogen dioxide concentration in the gas flow.
- the system further includes one or more conversion devices operably coupled to the ventilator where the conversion devices convert nitrogen dioxide into nitric oxide.
- a patient interface delivers nitric oxide to the patient and is operably coupled to the conversion devices.
- the system includes a humidifier that is placed prior to the first conversion device.
- the humidifier is integral with the conversion device.
- the system includes an active humidifier that is placed prior to a second conversion cartridge which is adjacent to the patient interface.
- the system allows oxygen and nitric oxide levels to be varied independently.
- the system also includes safeguards in the event of system failure.
- the main conversion cartridge in the system is designed to have sufficient capacity to convert the entire contents of more than one bottle of nitrogen dioxide in the event of system failure.
- a second conversion cartridge is also included as a redundant safety measure where the second conversion cartridge is able to convert the entire contents of a bottle of nitrogen dioxide into nitric oxide.
- FIG. 1 is a schematic view of one embodiment of a nitric oxide (NO) generating system.
- NO nitric oxide
- FIG. 2 is a block diagram of one embodiment of a NO generating system.
- FIG. 3 is a perspective view of one embodiment of a system for delivering NO to a patient.
- FIG. 4 is a cross-sectional view of one embodiment of a NO generating device.
- FIG. 5 is a block diagram of another embodiment of a NO generating device.
- NO nitric oxide
- NO gas having a concentration of approximately 2 to approximately 1000 ppm (e.g., greater than 2, 20, 40, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000. 1200, 1400, 1600, 1800 and 2000 ppm) may be delivered to a patient.
- high doses of NO may be used to prevent, reverse, or limit the progression of disorders which can include, but are not limited to, acute pulmonary vasoconstriction, traumatic injury, aspiration or inhalation injury, fat embolism in the lung, acidosis, inflammation of the lung, adult respiratory distress syndrome, acute pulmonary edema, acute mountain sickness, post cardiac surgery acute pulmonary hypertension, persistent pulmonary hypertension of a newborn, perinatal aspiration syndrome, haline membrane disease, acute pulmonary thromboembolism, heparin-protamine reactions, sepsis, asthma, status asthmaticus, or hypoxia.
- NO can also be used to treat chronic pulmonary hypertension, bronchopulmonary dysplasia, chronic pulmonary thromboembolism, idiopathic pulmonary hypertension, primary pulmonary hypertension, or chronic hypoxia.
- NO gas nitrogen dioxide
- NO gas is stored in heavy gas bottles with nitrogen and no traces of oxygen.
- NO gas is mixed with air or oxygen with specialized injectors and complex ventilators, and the mixing process is monitored with equipment having sensitive microprocessors and electronics. All this equipment is required in order to ensure that NO is not oxidized into NO 2 during the mixing process since NO 2 is highly toxic.
- this equipment is not conducive to use in routine hospital and non-medical facility settings since the size, cost, complexity, and safety issues restrict the operation of this equipment to highly-trained professionals who are specially trained in its use.
- FIGS. 1-2 illustrate one embodiment of a system 100 that generates NO from NO 2 .
- the system 100 may be used in a medical setting such as, but not limited to, an operating theatre or an intensive care unit.
- the system 100 includes a gas source 102 containing NO 2 premixed in air or oxygen.
- the system 100 includes two gas sources 102 where one bottle is a standby in the event the first bottle becomes depleted.
- the system 100 may include a single gas source capable of producing NO.
- the system 100 may include a plurality of gas sources capable of producing NO.
- a valve (not shown) is coupled to the gas sources and allows for switching between the gas sources.
- the system 100 includes a ventilator 104 connected to the gas sources 102 capable of producing NO in addition to a gas source of compressed air 106 and oxygen 108 , as shown in FIG. 1 .
- the ventilator 104 also includes components such as mixing valves (not shown) that are resistant to NO 2 gas.
- the mixing valves (not shown) used in the ventilator 102 are manufactured by Bio-Med Devices of Guilford, Conn.
- the ventilator 104 is also provided with controls to independently vary the concentration of NO 2 and oxygen. Accordingly, the mixing valves and the ventilator 104 regulate and adjust the concentration of the gas so that it is at a proper concentration to be converted into a therapeutic dose of NO at the main conversion cartridge 110 . Additionally, the ventilator 104 can be adjusted to provide the proper gas flow pattern.
- the gas passes through the main conversion cartridge 110 where NO 2 in the gas flow is converted to NO.
- a passive humidifier (not shown) is positioned to the main cartridge 110 .
- the passive humidifier operates at a dew point of approximately less than 18° C. (not shown) that may be separate or integral with the main cartridge 110 .
- the NO gas generated by the main conversion cartridge 110 then flows through an active humidifier 114 , which provides moisture to the patient and also extends the lifespan of the conversion cartridge 112 .
- the humidified NO gas then filters through a secondary cartridge 112 (also referred to as a recuperator) to convert any NO 2 in the gas lines into NO.
- the NO gas (in air or oxygen) is then delivered to a patient via a patient interface 116 .
- the patient interface 116 may be a mouth piece, nasal cannula, face mask, or fully-sealed face mask.
- the active humidifier brings the moisture content of the NO gas (and air/oxygen) up to a dew point of approximately 32 to 37° C., thereby preventing moisture loss from the lungs.
- a single humidifier 114 is positioned between the conversion cartridges 110 , 112 .
- the system 100 may include humidifiers 114 placed prior to each conversion cartridge 110 , 112 .
- the humidifier 114 is a separate device, but it is contemplated that the humidifier may be an integral component of each conversion cartridge (not shown).
- the humidifier 114 used in the system 100 is manufactured by Fisher and Pykell.
- the system 100 may include one or more safety features.
- the main conversion cartridge 110 is sized so that it has excess capacity to convert NO 2 into NO.
- the main conversion cartridge 110 is sized to convert the entire contents of more than one gas bottle 102 of NO 2 gas. If the main conversion cartridge 110 were to fail, the recuperator cartridge 112 has sufficient capacity to convert the entire contents of a gas bottle 102 .
- NO 2 and the NO gas concentrations may be monitored after the main conversion cartridge 110 .
- the gas concentrations of NO and NO 2 may be monitored by one or more NO and NO 2 detectors manufactured by Cardinal Healthcare, Viasys Division. If any NO 2 is detected, visual and/or auditory alarms would be presented to the operator.
- recuperator cartridge 112 would convert any NO 2 that was present in the gas lines back into NO. This function is important at very high NO levels (>40 ppm) as well as during start up of the system 100 . Additionally, the recuperator cartridge 112 makes it unnecessary to flush the lines to remove NO 2 , since the NO 2 in the lines would be converted to NO by the recuperator prior to delivery to a patient.
- FIG. 3 illustrates another embodiment of a system 300 for delivering NO to a patient.
- the system 300 is provided on a wheeled stand 302 .
- the system 300 includes a ventilator 102 that is resistant to NO 2 gas.
- the system 300 also includes two gas sources 102 for providing NO 2 gas.
- a third gas source 306 is also mounted in the center of the stand 302 .
- the third gas source 306 contains NO 2 in air or oxygen at an appropriate concentration.
- the third gas source 306 is also connected to the ventilator 102 by gas plumbing and is in a standby mode. In the event of a disruption of the NO 2 gas, compressed air, or compressed oxygen, an automatic series of valves would shut down the feed of gas to the ventilator 104 and replace it with gas from the back up gas source 306 .
- the third gas source 306 is available as substitute for the system 300 .
- the third gas source 306 includes a NO conversion cartridge 308 and may be used to deliver NO to the patient by means of a handheld ventilator (not shown).
- FIG. 4 illustrates one embodiment of a device 400 that generates NO from NO 2 .
- the device 100 which may be referred to as a NO generation cartridge, a GENO cartridge, a GENO cylinder, or a recuperator, includes a body 402 having an inlet 404 and an outlet 406 .
- the inlet 404 and outlet 406 are sized to engage gas plumbing lines or directly couple to other components such as, but not limited to, gas tanks, regulators, valves, humidifiers, patient interfaces, or recuperators. Additionally, the inlet 404 and outlet 406 may include threads or specially designed fittings to engage these components.
- the body 402 is generally cylindrical in shape and defines a cavity that holds a porous solid matrix 408 .
- the porous solid matrix 408 is a mixture of a surface-activated material such as, but not limited to, silica gel and one or more suitable thermoplastic resins.
- the thermoplastic resin when cured, provides a rigid structure to support the surface-activated material.
- the porous thermoplastic resin may be shaped or molded into any form.
- the porous solid matrix 408 is composed of at least 20% silica gel. In another embodiment, the porous solid matrix 408 includes approximately 20% to approximately 60% silica gel. In yet another embodiment, the porous solid matrix 408 is composed of 50% silica gel. As those skilled in the art will appreciate, any ratio of silica gel to thermoplastic resin is contemplated so long as the mechanical and structural strength of the porous solid matrix 408 is maintained. In one embodiment, the densities of the silica gel and the thermoplastic resin are generally similar in order to achieve a uniform mixture and, ultimately, a uniform porous solid matrix 408 .
- the porous solid matrix 408 also has a cylindrical shape having an inner bore 412 .
- the porous solid matrix may have any shape known or developed in the art.
- the porous solid matrix 408 is positioned within the body 402 such that a space 414 is formed between the body and the porous solid matrix.
- a diverter 410 is positioned between the inlet and the porous solid matrix 408 .
- the diverter 410 directs the gas flow to the outer diameter of the porous solid matrix 108 (as shown by the white arrows). Gas flow is forced through the porous solid matrix 108 whereby any NO 2 is converted into NO (as shown by the darkened arrows).
- the porous solid matrix 408 allows the device 400 to be used in any orientation (e.g., horizontally, vertically, or at any angle). Additionally, the porous solid matrix 408 provides a rigid structure suitable to withstand vibrations and abuse associated with shipping and handling.
- FIG. 5 illustrates another embodiment of a conversion cartridge 500 that generates NO from NO 2 .
- the conversion cartridge 500 includes an inlet 505 and an outlet 510 .
- Porous filters or a screen and glass wool 515 are located at both the inlet 505 and the outlet 510 , and the remainder of the cartridge 500 is filled with a surface-active material 520 that is soaked with a saturated solution of antioxidant in water to coat the surface-active material.
- the antioxidant is ascorbic acid.
- an air flow having NO 2 is received through the inlet 505 and the air flow is fluidly communicated to the outlet 110 through the surface-active material 520 coated with the aqueous antioxidant.
- the general process is effective at converting NO 2 to NO at ambient temperatures.
- the inlet 505 may receive the air flow having NO 2 , for example, from a pressurized bottle of NO 2 , which also may be referred to as a tank of NO 2 .
- the inlet 505 also may receive an air flow with NO 2 in nitrogen (N 2 ), air, or oxygen (O 2 ).
- the inlet 505 may also receive the air flow having NO 2 from an air pump that fluidly communicates an air flow over a permeation or a diffusion tube (not shown). The conversion occurs over a wide concentration range. Experiments have been carried out at concentrations in air of from about 0.2 ppm NO 2 to about 100 ppm NO 2 , and even to over 1000 ppm NO 2 .
- a cartridge that was approximately 5 inches long and had a diameter of 0.8-inches was packed with silica gel that had first been soaked in a saturated aqueous solution of ascorbic acid.
- the moist silica gel was prepared using ascorbic acid (i.e., vitamin C) designated as A.C.S. reagent grade 99.1% pure from Aldrich Chemical Company and silica gel from Fischer Scientific International, Inc., designated as S8 32-1, 40 of Grade of 35 to 70 sized mesh.
- Ascorbic acid i.e., vitamin C
- silica gel from Fischer Scientific International, Inc., designated as S8 32-1, 40 of Grade of 35 to 70 sized mesh.
- Other sizes of silica gel also are effective as long as the particles are small enough and the pore size is such as to provide sufficient surface area.
- the silica gel was moistened with a saturated solution of ascorbic acid that had been prepared by mixing 35% by weight ascorbic acid in water, stirring, and straining the water/ascorbic acid mixture through the silica gel, followed by draining.
- the silica gel is dried to about 30% moisture by weight. It has been found that the conversion of NO 2 to NO proceeds well when the silica gel coated with ascorbic acid is moist. The conversion of NO 2 to NO does not proceed well in an aqueous solution of ascorbic acid alone.
- the cartridge filled with the moist silica gel/ascorbic acid was able to convert 1000 ppm of NO 2 in air to NO at a flow rate of 150 ml per minute, quantitatively, non-stop for over 12 days.
- a wide variety of flow rates and NO 2 concentrations have been successfully tested, ranging from only a few ml per minute to flow rates of up to approximately 5,000 ml per minute, up to flow rates of approximately 80,000 ml per minute.
- the reaction also proceeds using other common antioxidants, such as variants of vitamin E (e.g., alpha tocopherol and gamma tocopherol).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the benefit of prior U.S. Provisional Application No. 61/090,616, filed on Aug. 21, 2008, which is incorporated by reference in its entirety.
- This description relates to systems for generating nitric oxide.
- Nitric oxide (NO), also known as nitrosyl radical, is a free radical that is an important signaling molecule. For example, NO causes smooth muscles in blood vessels to relax, thereby resulting in vasodilation and increased blood flow through the blood vessel. These effects are limited to small biological regions since NO is highly reactive with a lifetime of a few seconds and is quickly metabolized in the body.
- Typically, NO gas is supplied in a bottled gaseous form diluted in nitrogen gas (N2). Great care has to be taken to prevent the presence of even trace amounts of oxygen (O2) in the tank of NO gas because NO, in the presence of O2, is oxidized into nitrogen dioxide (NO2). Unlike NO, the part per million levels of NO2 gas is highly toxic if inhaled and can form nitric and nitrous acid in the lungs.
- Briefly, and in general terms, various systems generating nitric oxide are disclosed herein. According to one embodiment, the system includes a first gas source providing nitrogen dioxide mixed in air or oxygen, and a second gas source supplying compressed air and/or compressed oxygen. The system also includes a ventilator coupled to the first and second gas sources, wherein the ventilator is resistant to nitrogen dioxide. The ventilator regulates gas flow and allows for the adjustment of nitrogen dioxide concentration in the gas flow. The system further includes one or more conversion devices operably coupled to the ventilator where the conversion devices convert nitrogen dioxide into nitric oxide. A patient interface delivers nitric oxide to the patient and is operably coupled to the conversion devices.
- In another embodiment, the system includes a humidifier that is placed prior to the first conversion device. In yet another embodiment, the humidifier is integral with the conversion device. Optionally, the system includes an active humidifier that is placed prior to a second conversion cartridge which is adjacent to the patient interface.
- The system allows oxygen and nitric oxide levels to be varied independently. The system also includes safeguards in the event of system failure. In one embodiment, the main conversion cartridge in the system is designed to have sufficient capacity to convert the entire contents of more than one bottle of nitrogen dioxide in the event of system failure. In another embodiment, a second conversion cartridge is also included as a redundant safety measure where the second conversion cartridge is able to convert the entire contents of a bottle of nitrogen dioxide into nitric oxide.
- Other features will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate by way of example, the features of the various embodiments.
-
FIG. 1 is a schematic view of one embodiment of a nitric oxide (NO) generating system. -
FIG. 2 is a block diagram of one embodiment of a NO generating system. -
FIG. 3 is a perspective view of one embodiment of a system for delivering NO to a patient. -
FIG. 4 is a cross-sectional view of one embodiment of a NO generating device. -
FIG. 5 is a block diagram of another embodiment of a NO generating device. - Various systems and devices for generating nitric oxide (NO) are disclosed herein. Generally, NO is inhaled or otherwise delivered to a patient's lungs. Since NO is inhaled, much higher local doses can be achieved without concomitant vasodilation of the other blood vessels in the body. Accordingly, NO gas having a concentration of approximately 2 to approximately 1000 ppm (e.g., greater than 2, 20, 40, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000. 1200, 1400, 1600, 1800 and 2000 ppm) may be delivered to a patient. Accordingly, high doses of NO may be used to prevent, reverse, or limit the progression of disorders which can include, but are not limited to, acute pulmonary vasoconstriction, traumatic injury, aspiration or inhalation injury, fat embolism in the lung, acidosis, inflammation of the lung, adult respiratory distress syndrome, acute pulmonary edema, acute mountain sickness, post cardiac surgery acute pulmonary hypertension, persistent pulmonary hypertension of a newborn, perinatal aspiration syndrome, haline membrane disease, acute pulmonary thromboembolism, heparin-protamine reactions, sepsis, asthma, status asthmaticus, or hypoxia. NO can also be used to treat chronic pulmonary hypertension, bronchopulmonary dysplasia, chronic pulmonary thromboembolism, idiopathic pulmonary hypertension, primary pulmonary hypertension, or chronic hypoxia.
- Currently, approved devices and methods for delivering inhaled NO gas require complex and heavy equipment, and they are limited in their output to 80 ppm of NO because of the presence of the toxic compound, nitrogen dioxide (NO2). NO gas is stored in heavy gas bottles with nitrogen and no traces of oxygen. NO gas is mixed with air or oxygen with specialized injectors and complex ventilators, and the mixing process is monitored with equipment having sensitive microprocessors and electronics. All this equipment is required in order to ensure that NO is not oxidized into NO2 during the mixing process since NO2 is highly toxic. However, this equipment is not conducive to use in routine hospital and non-medical facility settings since the size, cost, complexity, and safety issues restrict the operation of this equipment to highly-trained professionals who are specially trained in its use.
-
FIGS. 1-2 illustrate one embodiment of asystem 100 that generates NO from NO2. Thesystem 100 may be used in a medical setting such as, but not limited to, an operating theatre or an intensive care unit. Thesystem 100 includes agas source 102 containing NO2 premixed in air or oxygen. As shown inFIG. 1 , thesystem 100 includes twogas sources 102 where one bottle is a standby in the event the first bottle becomes depleted. Alternatively, thesystem 100 may include a single gas source capable of producing NO. In another embodiment, thesystem 100 may include a plurality of gas sources capable of producing NO. Optionally, if more than one gas source is provided with thesystem 100, a valve (not shown) is coupled to the gas sources and allows for switching between the gas sources. - The
system 100 includes aventilator 104 connected to thegas sources 102 capable of producing NO in addition to a gas source of compressedair 106 andoxygen 108, as shown inFIG. 1 . Theventilator 104 also includes components such as mixing valves (not shown) that are resistant to NO2 gas. In one embodiment, the mixing valves (not shown) used in theventilator 102 are manufactured by Bio-Med Devices of Guilford, Conn. Theventilator 104 is also provided with controls to independently vary the concentration of NO2 and oxygen. Accordingly, the mixing valves and theventilator 104 regulate and adjust the concentration of the gas so that it is at a proper concentration to be converted into a therapeutic dose of NO at themain conversion cartridge 110. Additionally, theventilator 104 can be adjusted to provide the proper gas flow pattern. - As shown in
FIGS. 1-2 , the gas passes through themain conversion cartridge 110 where NO2 in the gas flow is converted to NO. In one embodiment, a passive humidifier (not shown) is positioned to themain cartridge 110. The passive humidifier operates at a dew point of approximately less than 18° C. (not shown) that may be separate or integral with themain cartridge 110. The NO gas generated by themain conversion cartridge 110 then flows through anactive humidifier 114, which provides moisture to the patient and also extends the lifespan of theconversion cartridge 112. The humidified NO gas then filters through a secondary cartridge 112 (also referred to as a recuperator) to convert any NO2 in the gas lines into NO. The NO gas (in air or oxygen) is then delivered to a patient via apatient interface 116. Thepatient interface 116 may be a mouth piece, nasal cannula, face mask, or fully-sealed face mask. The active humidifier brings the moisture content of the NO gas (and air/oxygen) up to a dew point of approximately 32 to 37° C., thereby preventing moisture loss from the lungs. - As shown in
FIGS. 1-2 , asingle humidifier 114 is positioned between theconversion cartridges system 100 may includehumidifiers 114 placed prior to eachconversion cartridge FIGS. 1-2 , thehumidifier 114 is a separate device, but it is contemplated that the humidifier may be an integral component of each conversion cartridge (not shown). According to one embodiment, thehumidifier 114 used in thesystem 100 is manufactured by Fisher and Pykell. - Additionally, the
system 100 may include one or more safety features. In one embodiment, themain conversion cartridge 110 is sized so that it has excess capacity to convert NO2 into NO. For example, themain conversion cartridge 110 is sized to convert the entire contents of more than onegas bottle 102 of NO2 gas. If themain conversion cartridge 110 were to fail, therecuperator cartridge 112 has sufficient capacity to convert the entire contents of agas bottle 102. In yet another embodiment, NO2 and the NO gas concentrations may be monitored after themain conversion cartridge 110. In one embodiment, the gas concentrations of NO and NO2 may be monitored by one or more NO and NO2 detectors manufactured by Cardinal Healthcare, Viasys Division. If any NO2 is detected, visual and/or auditory alarms would be presented to the operator. The alarms will allow the operator to correct the problem, but therecuperator cartridge 112 would convert any NO2 that was present in the gas lines back into NO. This function is important at very high NO levels (>40 ppm) as well as during start up of thesystem 100. Additionally, therecuperator cartridge 112 makes it unnecessary to flush the lines to remove NO2, since the NO2 in the lines would be converted to NO by the recuperator prior to delivery to a patient. -
FIG. 3 illustrates another embodiment of a system 300 for delivering NO to a patient. The system 300 is provided on awheeled stand 302. The system 300 includes aventilator 102 that is resistant to NO2 gas. The system 300 also includes twogas sources 102 for providing NO2 gas. Additionally, athird gas source 306 is also mounted in the center of thestand 302. Thethird gas source 306 contains NO2 in air or oxygen at an appropriate concentration. Thethird gas source 306 is also connected to theventilator 102 by gas plumbing and is in a standby mode. In the event of a disruption of the NO2 gas, compressed air, or compressed oxygen, an automatic series of valves would shut down the feed of gas to theventilator 104 and replace it with gas from the back upgas source 306. This safety feature is on standby mode and may be implemented within the time frame of a single breath. If theventilator 104 malfunctions, thethird gas source 306 is available as substitute for the system 300. Thethird gas source 306 includes aNO conversion cartridge 308 and may be used to deliver NO to the patient by means of a handheld ventilator (not shown). - Conversion Cartridges
-
FIG. 4 illustrates one embodiment of adevice 400 that generates NO from NO2. Thedevice 100, which may be referred to as a NO generation cartridge, a GENO cartridge, a GENO cylinder, or a recuperator, includes abody 402 having aninlet 404 and anoutlet 406. Theinlet 404 andoutlet 406 are sized to engage gas plumbing lines or directly couple to other components such as, but not limited to, gas tanks, regulators, valves, humidifiers, patient interfaces, or recuperators. Additionally, theinlet 404 andoutlet 406 may include threads or specially designed fittings to engage these components. - As shown in
FIG. 4 , thebody 402 is generally cylindrical in shape and defines a cavity that holds a poroussolid matrix 408. According to one embodiment, the poroussolid matrix 408 is a mixture of a surface-activated material such as, but not limited to, silica gel and one or more suitable thermoplastic resins. The thermoplastic resin, when cured, provides a rigid structure to support the surface-activated material. Additionally, the porous thermoplastic resin may be shaped or molded into any form. - According to one embodiment, the porous
solid matrix 408 is composed of at least 20% silica gel. In another embodiment, the poroussolid matrix 408 includes approximately 20% to approximately 60% silica gel. In yet another embodiment, the poroussolid matrix 408 is composed of 50% silica gel. As those skilled in the art will appreciate, any ratio of silica gel to thermoplastic resin is contemplated so long as the mechanical and structural strength of the poroussolid matrix 408 is maintained. In one embodiment, the densities of the silica gel and the thermoplastic resin are generally similar in order to achieve a uniform mixture and, ultimately, a uniform poroussolid matrix 408. - As shown in
FIG. 4 , the poroussolid matrix 408 also has a cylindrical shape having aninner bore 412. In other embodiments, the porous solid matrix may have any shape known or developed in the art. The poroussolid matrix 408 is positioned within thebody 402 such that aspace 414 is formed between the body and the porous solid matrix. At theinlet end 404 of thebody 402, adiverter 410 is positioned between the inlet and the poroussolid matrix 408. Thediverter 410 directs the gas flow to the outer diameter of the porous solid matrix 108 (as shown by the white arrows). Gas flow is forced through the poroussolid matrix 108 whereby any NO2 is converted into NO (as shown by the darkened arrows). NO gas then exits theoutlet 406 of thedevice 400. The poroussolid matrix 408 allows thedevice 400 to be used in any orientation (e.g., horizontally, vertically, or at any angle). Additionally, the poroussolid matrix 408 provides a rigid structure suitable to withstand vibrations and abuse associated with shipping and handling. -
FIG. 5 illustrates another embodiment of aconversion cartridge 500 that generates NO from NO2. Theconversion cartridge 500 includes aninlet 505 and anoutlet 510. Porous filters or a screen andglass wool 515 are located at both theinlet 505 and theoutlet 510, and the remainder of thecartridge 500 is filled with a surface-active material 520 that is soaked with a saturated solution of antioxidant in water to coat the surface-active material. In the example ofFIG. 5 , the antioxidant is ascorbic acid. - In a general process for converting NO2 to NO, an air flow having NO2 is received through the
inlet 505 and the air flow is fluidly communicated to theoutlet 110 through the surface-active material 520 coated with the aqueous antioxidant. As long as the surface-active material remains moist and the antioxidant has not been used up in the conversion, the general process is effective at converting NO2 to NO at ambient temperatures. - The
inlet 505 may receive the air flow having NO2, for example, from a pressurized bottle of NO2, which also may be referred to as a tank of NO2. Theinlet 505 also may receive an air flow with NO2 in nitrogen (N2), air, or oxygen (O2). Theinlet 505 may also receive the air flow having NO2 from an air pump that fluidly communicates an air flow over a permeation or a diffusion tube (not shown). The conversion occurs over a wide concentration range. Experiments have been carried out at concentrations in air of from about 0.2 ppm NO2 to about 100 ppm NO2, and even to over 1000 ppm NO2. In one example, a cartridge that was approximately 5 inches long and had a diameter of 0.8-inches was packed with silica gel that had first been soaked in a saturated aqueous solution of ascorbic acid. Other sizes of the cartridge are also possible. The moist silica gel was prepared using ascorbic acid (i.e., vitamin C) designated as A.C.S. reagent grade 99.1% pure from Aldrich Chemical Company and silica gel from Fischer Scientific International, Inc., designated as S8 32-1, 40 of Grade of 35 to 70 sized mesh. Other sizes of silica gel also are effective as long as the particles are small enough and the pore size is such as to provide sufficient surface area. - The silica gel was moistened with a saturated solution of ascorbic acid that had been prepared by mixing 35% by weight ascorbic acid in water, stirring, and straining the water/ascorbic acid mixture through the silica gel, followed by draining. In one embodiment, the silica gel is dried to about 30% moisture by weight. It has been found that the conversion of NO2 to NO proceeds well when the silica gel coated with ascorbic acid is moist. The conversion of NO2 to NO does not proceed well in an aqueous solution of ascorbic acid alone.
- The cartridge filled with the moist silica gel/ascorbic acid was able to convert 1000 ppm of NO2 in air to NO at a flow rate of 150 ml per minute, quantitatively, non-stop for over 12 days. A wide variety of flow rates and NO2 concentrations have been successfully tested, ranging from only a few ml per minute to flow rates of up to approximately 5,000 ml per minute, up to flow rates of approximately 80,000 ml per minute. The reaction also proceeds using other common antioxidants, such as variants of vitamin E (e.g., alpha tocopherol and gamma tocopherol).
- The various embodiments described above are provided by way of illustration only and should not be construed to limit the claimed invention. Those skilled in the art will readily recognize various modifications and changes that may be made to the claimed invention without following the example embodiments and applications illustrated and described herein, and without departing from the true spirit and scope of the claimed invention, which is set forth in the following claims.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/444,791 US20200139071A1 (en) | 2008-08-21 | 2019-06-18 | Systems for generating nitric oxide |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9061608P | 2008-08-21 | 2008-08-21 | |
US12/541,141 US8701657B2 (en) | 2008-08-21 | 2009-08-13 | Systems for generating nitric oxide |
US14/169,968 US20140144444A1 (en) | 2008-08-21 | 2014-01-31 | Systems for generating nitric oxide |
US16/444,791 US20200139071A1 (en) | 2008-08-21 | 2019-06-18 | Systems for generating nitric oxide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/169,968 Continuation US20140144444A1 (en) | 2008-08-21 | 2014-01-31 | Systems for generating nitric oxide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200139071A1 true US20200139071A1 (en) | 2020-05-07 |
Family
ID=41695167
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/541,141 Expired - Fee Related US8701657B2 (en) | 2008-08-21 | 2009-08-13 | Systems for generating nitric oxide |
US14/169,968 Abandoned US20140144444A1 (en) | 2008-08-21 | 2014-01-31 | Systems for generating nitric oxide |
US16/444,791 Abandoned US20200139071A1 (en) | 2008-08-21 | 2019-06-18 | Systems for generating nitric oxide |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/541,141 Expired - Fee Related US8701657B2 (en) | 2008-08-21 | 2009-08-13 | Systems for generating nitric oxide |
US14/169,968 Abandoned US20140144444A1 (en) | 2008-08-21 | 2014-01-31 | Systems for generating nitric oxide |
Country Status (6)
Country | Link |
---|---|
US (3) | US8701657B2 (en) |
EP (1) | EP2326382B1 (en) |
JP (2) | JP5688851B2 (en) |
AU (1) | AU2009282988B2 (en) |
CA (1) | CA2734790C (en) |
WO (1) | WO2010021944A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10946163B2 (en) | 2017-02-27 | 2021-03-16 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
US11033705B2 (en) | 2017-02-27 | 2021-06-15 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
US11045620B2 (en) | 2019-05-15 | 2021-06-29 | Third Pole, Inc. | Electrodes for nitric oxide generation |
US11479464B2 (en) | 2019-05-15 | 2022-10-25 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
US11691879B2 (en) | 2020-01-11 | 2023-07-04 | Third Pole, Inc. | Systems and methods for nitric oxide generation with humidity control |
US11827989B2 (en) | 2020-06-18 | 2023-11-28 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
US11833309B2 (en) | 2017-02-27 | 2023-12-05 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
JP5421530B2 (en) | 2004-08-18 | 2014-02-19 | ゲノ エルエルシー | Conversion of nitrogen dioxide (NO2) to nitrogen oxide (NO) |
CA2713049C (en) | 2008-01-28 | 2017-02-28 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
CA2763804C (en) | 2009-06-22 | 2018-02-06 | Geno Llc | Nitric oxide therapies |
AU2010321707B2 (en) * | 2009-11-20 | 2016-03-17 | VERO Biotech LLC. | Nitric oxide delivery system |
CA2819854A1 (en) | 2010-12-03 | 2012-06-07 | Geno Llc | Nitric oxide treatments |
WO2012166534A1 (en) | 2011-05-27 | 2012-12-06 | Geno Llc | Method of determining vasoreactivity using inhaled nitric oxide |
ES2644926T3 (en) | 2011-08-10 | 2017-12-01 | Fisher&Paykel Healthcare Limited | Duct connector for a patient breathing device |
WO2014071349A1 (en) * | 2012-11-05 | 2014-05-08 | Geno Llc | Method of mixing gases including nitric oxide |
AU2013337269A1 (en) * | 2012-11-05 | 2015-05-21 | Geno Llc | Dual platform system for the delivery of nitric oxide |
US10525226B2 (en) * | 2014-05-14 | 2020-01-07 | Mallinckrodt Hospital Products IP Limited | Systems and methods for indicating lifetime of an NO2-to-NO reactor cartridge used to deliver NO for inhalation therapy to a patient |
JP2017534422A (en) | 2014-10-20 | 2017-11-24 | ゲノ エルエルシー | Nitrogen dioxide storage cassette |
RU2597131C2 (en) * | 2014-12-31 | 2016-09-10 | Евгений Владимирович Печёнкин | Method and device for forming high-speed no-containing gas flow for action on biological object |
CN112891694A (en) | 2015-03-31 | 2021-06-04 | 费雪派克医疗保健有限公司 | Apparatus for use in a respiratory support system |
EP4186548A1 (en) | 2015-04-02 | 2023-05-31 | Hill-Rom Services PTE. LTD. | Mask leakage detection for a respiratory device |
AU2016267090A1 (en) * | 2015-05-25 | 2017-12-07 | VERO Biotech LLC. | Nitric oxide treatment system and method |
US20190290868A1 (en) * | 2018-03-26 | 2019-09-26 | Jarom C. HEATON | Portable anesthesia apparatus and transportation cart |
US11672938B1 (en) | 2018-07-18 | 2023-06-13 | Vero Biotech LLC | Start-up protocols for nitric oxide delivery device |
US11754538B1 (en) * | 2018-07-18 | 2023-09-12 | Vero Biotech Inc. | Method and apparatus for automatic calibration |
USD1006981S1 (en) | 2019-09-06 | 2023-12-05 | Fisher & Paykel Healthcare Limited | Breathing conduit |
USD948027S1 (en) | 2019-09-10 | 2022-04-05 | Fisher & Paykel Healthcare Limited | Connector for a breathing conduit |
USD974551S1 (en) | 2020-12-09 | 2023-01-03 | Fisher & Paykel Healthcare Limited | Connector assembly and connector |
USD995758S1 (en) | 2021-06-11 | 2023-08-15 | Fisher & Paykel Healthcare Limited | Tube assembly and connector |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US283447A (en) * | 1883-08-21 | Sight for fire-arms | ||
US48779A (en) * | 1865-07-11 | Oscar hase | ||
US2127561A (en) * | 1936-04-29 | 1938-08-23 | Du Pont | Heat exchange catalytic converter |
US3272336A (en) * | 1965-04-05 | 1966-09-13 | Wix Corp | Liquid purifier and cleaner |
JPS5636977B2 (en) * | 1973-07-05 | 1981-08-27 | ||
US4256101A (en) * | 1979-03-05 | 1981-03-17 | Bourns Medical Systems, Inc. | Thermistor assist sensing |
US4374094A (en) * | 1981-10-29 | 1983-02-15 | Chevron Research Company | Method and apparatus for uniform flow through radial reactor centerpipes |
US4459982A (en) * | 1982-09-13 | 1984-07-17 | Bear Medical Systems, Inc. | Servo-controlled demand regulator for respiratory ventilator |
US4602653A (en) * | 1984-11-01 | 1986-07-29 | Bear Medical Systems, Inc. | Electronically-controlled gas blending system |
US4668494A (en) * | 1984-12-24 | 1987-05-26 | Foster Wheeler Energy Corporation | Method of using solar energy in a chemical synthesis process |
US5514205A (en) * | 1994-12-30 | 1996-05-07 | Awaji; Toshio | Apparatus for removing harmful objects from a gas |
DE19612289A1 (en) * | 1996-03-28 | 1997-10-02 | Messer Griesheim Gmbh | Method and device for reducing risks in inhaled NO therapy |
US5752506A (en) * | 1996-08-21 | 1998-05-19 | Bunnell Incorporated | Ventilator system |
JPH10314309A (en) * | 1997-05-14 | 1998-12-02 | Boc Group Inc:The | Method and apparatus for generating nitrogen oxide gas mixture |
US6581599B1 (en) * | 1999-11-24 | 2003-06-24 | Sensormedics Corporation | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
US6758214B2 (en) * | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
US6532956B2 (en) * | 2000-03-30 | 2003-03-18 | Respironics, Inc. | Parameter variation for proportional assist ventilation or proportional positive airway pressure support devices |
US7025869B2 (en) * | 2001-09-05 | 2006-04-11 | Cyterra Corporation | Nitric oxide delivery system |
US7387123B2 (en) * | 2001-11-30 | 2008-06-17 | Viasys Manufacturing, Inc. | Gas identification system and volumetrically correct gas delivery system |
US20040081580A1 (en) * | 2002-09-10 | 2004-04-29 | Doug Hole | Use of nitric oxide and a device in the therapeutic management of pathogens in mammals |
US7520280B2 (en) * | 2003-04-08 | 2009-04-21 | William Gordon | Rebreather apparatus |
CA2563493A1 (en) * | 2004-05-11 | 2005-11-24 | Sensormedics Corporation | Intermittent dosing of nitric oxide gas |
JP5421530B2 (en) | 2004-08-18 | 2014-02-19 | ゲノ エルエルシー | Conversion of nitrogen dioxide (NO2) to nitrogen oxide (NO) |
US7618594B2 (en) * | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
JP3873999B2 (en) * | 2004-09-09 | 2007-01-31 | いすゞ自動車株式会社 | Induction structure and exhaust gas purification device |
JP4671772B2 (en) * | 2004-12-22 | 2011-04-20 | 三菱電機株式会社 | Apparatus and method for treating and recovering gaseous hydrocarbons |
US7870857B2 (en) | 2005-05-23 | 2011-01-18 | Aeon Research And Technology, Inc. | Patient interface assemblies for use in ventilator systems to deliver medication to a patient |
US8561611B2 (en) * | 2005-06-21 | 2013-10-22 | Ric Investments, Llc | Respiratory device measurement system |
US20070181126A1 (en) * | 2006-02-08 | 2007-08-09 | Tolmie Craig R | Method and apparatus for ventilating a patient with a breathing gas mixture formed from nitric oxide, air, and oxygen |
JP2007332849A (en) * | 2006-06-14 | 2007-12-27 | Hino Motors Ltd | Exhaust gas purification apparatus |
GB0703172D0 (en) * | 2007-02-19 | 2007-03-28 | Pa Knowledge Ltd | Printed circuit boards |
-
2009
- 2009-08-13 US US12/541,141 patent/US8701657B2/en not_active Expired - Fee Related
- 2009-08-14 CA CA2734790A patent/CA2734790C/en not_active Expired - Fee Related
- 2009-08-14 JP JP2011523893A patent/JP5688851B2/en not_active Expired - Fee Related
- 2009-08-14 WO PCT/US2009/053949 patent/WO2010021944A1/en active Application Filing
- 2009-08-14 AU AU2009282988A patent/AU2009282988B2/en not_active Ceased
- 2009-08-14 EP EP09808649.9A patent/EP2326382B1/en not_active Not-in-force
-
2014
- 2014-01-31 US US14/169,968 patent/US20140144444A1/en not_active Abandoned
- 2014-07-25 JP JP2014151601A patent/JP5977786B2/en not_active Expired - Fee Related
-
2019
- 2019-06-18 US US16/444,791 patent/US20200139071A1/en not_active Abandoned
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10946163B2 (en) | 2017-02-27 | 2021-03-16 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
US11033705B2 (en) | 2017-02-27 | 2021-06-15 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
US11376390B2 (en) | 2017-02-27 | 2022-07-05 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
US11524134B2 (en) | 2017-02-27 | 2022-12-13 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
US11554240B2 (en) | 2017-02-27 | 2023-01-17 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
US11833309B2 (en) | 2017-02-27 | 2023-12-05 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
US11911566B2 (en) | 2017-02-27 | 2024-02-27 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
US11045620B2 (en) | 2019-05-15 | 2021-06-29 | Third Pole, Inc. | Electrodes for nitric oxide generation |
US11479464B2 (en) | 2019-05-15 | 2022-10-25 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
US11478601B2 (en) | 2019-05-15 | 2022-10-25 | Third Pole, Inc. | Electrodes for nitric oxide generation |
US11691879B2 (en) | 2020-01-11 | 2023-07-04 | Third Pole, Inc. | Systems and methods for nitric oxide generation with humidity control |
US11827989B2 (en) | 2020-06-18 | 2023-11-28 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
Also Published As
Publication number | Publication date |
---|---|
AU2009282988B2 (en) | 2015-02-05 |
EP2326382A1 (en) | 2011-06-01 |
EP2326382A4 (en) | 2014-03-05 |
US20100043789A1 (en) | 2010-02-25 |
US20140144444A1 (en) | 2014-05-29 |
JP5688851B2 (en) | 2015-03-25 |
WO2010021944A1 (en) | 2010-02-25 |
CA2734790A1 (en) | 2010-02-25 |
AU2009282988A1 (en) | 2010-02-25 |
US8701657B2 (en) | 2014-04-22 |
CA2734790C (en) | 2018-10-16 |
EP2326382B1 (en) | 2018-11-28 |
JP5977786B2 (en) | 2016-08-24 |
JP2014237013A (en) | 2014-12-18 |
JP2012500093A (en) | 2012-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200139071A1 (en) | Systems for generating nitric oxide | |
US20200139073A1 (en) | Nitric oxide treatment system and method | |
US11744978B2 (en) | Systems and devices for generating nitric oxide | |
US20210316107A1 (en) | Conversion of nitrogen dioxide (no2) to nitric oxide (no) | |
US20140127330A1 (en) | Method of mixing gases including nitric oxide | |
AU2015202382A1 (en) | Systems for Generating Nitric Oxide | |
AU2012244330A1 (en) | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | |
Rounbehler et al. | Conversion of nitrogen dioxide (NO 2) to nitric oxide (NO) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: VERO BIOTECH LLC, GEORGIA Free format text: CHANGE OF NAME;ASSIGNOR:GENO LLC;REEL/FRAME:053891/0628 Effective date: 20180201 Owner name: GENO LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FINE, DAVID H.;VASQUEZ, GREGORY;JOHNSON, BRYAN;REEL/FRAME:053889/0564 Effective date: 20090910 |
|
AS | Assignment |
Owner name: RUNWAY GROWTH CREDIT FUND INC., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:VERO BIOTECH LLC;REEL/FRAME:054866/0589 Effective date: 20201229 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: VERO BIOTECH INC., GEORGIA Free format text: CHANGE OF NAME;ASSIGNOR:VERO BIOTECH LLC;REEL/FRAME:059085/0418 Effective date: 20211207 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC), FLORIDA Free format text: TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.);REEL/FRAME:066186/0611 Effective date: 20231229 |